Sugar Chain DCIR Ligands for Osteoclast Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current reports on DCIR-specific ligands are limited, and identifying diverse DCIR ligands is crucial for expanding therapeutic options for diseases where DCIR regulation is effective, particularly for autoimmune and bone metabolic disorders.
Innovation Solution
A novel dendritic cell immune receptor activator and inhibitor comprising a sugar chain with a specific structure, lacking sialic acid at non-reducing terminals, is used to activate or inhibit DCIR, thereby regulating osteoclast formation, dendritic cell differentiation/proliferation, and cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing DCIR-specific ligands are used, then some therapeutic effect is achieved, but the therapeutic options remain limited due to few identified ligands
Solution Approach 1:
The invention changes the chemical structure parameters of DCIR ligands by defining specific sugar chain structures with particular sialic acid configurations (or lack thereof) at non-reducing terminals. This structural parameter change enables identification of novel ligands with different therapeutic properties while maintaining DCIR binding capability, thus expanding therapeutic options without requiring discovery of entirely new molecule classes
Solution Approach 2:
The invention segments the ligand identification process by focusing on specific structural components (sugar chains with defined sialic acid patterns) rather than searching for complete novel molecules. This segmentation allows systematic identification and characterization of DCIR-binding structures, enabling discovery of multiple ligand variants based on a core structural motif
2Reliability
If DCIR is activated to inhibit osteoclast formation and dendritic cell proliferation, then autoimmune and bone metabolic diseases are treated, but the mechanism requires specific ligand binding that was previously insufficiently characterized
Solution Approach 1:
The invention establishes a feedback mechanism by using the identified sugar chain structures as probes to study DCIR ligand behavior and signaling pathways. The characterized ligands provide feedback information about DCIR function and mechanism, enabling better understanding and optimization of therapeutic approaches while ensuring reliable disease treatment
Solution Approach 2:
The invention uses specifically structured sugar chains as intermediary molecules that mediate between the therapeutic goal (DCIR activation) and the molecular mechanism (ligand binding). These intermediary ligands bridge the gap between desired therapeutic outcomes and underlying biological mechanisms, enabling both treatment and mechanistic understanding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sugar chain-based compounds effectively activate or inhibit DCIR, providing novel methods for treating autoimmune and bone metabolism diseases by modulating immune responses and bone resorption processes.
Implementation Method 1
A DCIR has a carbohydrate-recognition domain (CRD) in the extracellular region
Data Source
AI summary
A dendritic cell immune receptor activator, comprising a compound having a sugar chain as an active ingredient, the sugar chain having a basic structure represented by the following formula:wherein, in the formula, a sialic acid does not exist at two non-reducing terminals, and each of x and y independently represents 3 or 4.